Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coeptis Therapeutics Holdings (COEPW) Enterprise Value (2021 - 2025)

Coeptis Therapeutics Holdings has reported Enterprise Value over the past 5 years, most recently at -$5.8 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$5.8 million for Q4 2025, down 12131.83% from a year ago — trailing twelve months through Dec 2025 was -$5.8 million (down 12131.83% YoY), and the annual figure for FY2025 was -$5.8 million, down 12131.83%.
  • Enterprise Value for Q4 2025 was -$5.8 million at Coeptis Therapeutics Holdings, down from -$4.8 million in the prior quarter.
  • Over the last five years, Enterprise Value for COEPW hit a ceiling of -$47783.0 in Q4 2024 and a floor of -$7.4 million in Q3 2022.
  • Median Enterprise Value over the past 5 years was -$2.1 million (2023), compared with a mean of -$2.4 million.
  • Biggest five-year swings in Enterprise Value: surged 96.75% in 2024 and later tumbled 12131.83% in 2025.
  • Coeptis Therapeutics Holdings' Enterprise Value stood at -$2.2 million in 2021, then crashed by 73.95% to -$3.8 million in 2022, then surged by 61.25% to -$1.5 million in 2023, then surged by 96.75% to -$47783.0 in 2024, then tumbled by 12131.83% to -$5.8 million in 2025.
  • The last three reported values for Enterprise Value were -$5.8 million (Q4 2025), -$4.8 million (Q3 2025), and -$2.0 million (Q2 2025) per Business Quant data.